Identification of patient sub-groups with smoldering multiple myeloma (SMM) at high risk of progression to active disease (MM) is an important goal. 18F-FDG PET/CT (positron emission tomography (PET) integrated with computed tomography (PET/CT) using glucose labelled with the positron-emitting radionuclide 18 F) allows for assessing early skeletal involvement. Identification of osteolytic lesions by this technique has recently been incorporated into the updated International Myeloma Working Group criteria for MM diagnosis. However, no data are available regarding the impact of focal lesions (FLs) without underlying osteolysis on time to progression (TTP) to MM. We hence prospectively studied a cohort of 120 SMM patients with PET/CT. PET/CT was positive in 16% of patients (1 FL: 8, 2 FLs: 3, >3 FLs: 6, diffuse bone marrow involvement: 2). With a median follow-up of 2.2 years, 38% of patients progressed to MM, in a median time of 4 years, including 21% with skeletal involvement. The risk of progression of those with positive PET/CT was 3.00 (95% confidence interval 1.58-5.69, P=0.001), with a median TTP of 1.1 versus 4.5 years for PET/CT-negative patients. The probability of progression within 2 years was 58% for positive versus 33% for negative patients. In conclusion, PET/CT positivity significantly increased the risk of progression of SMM to MM. PET/CT could become a new tool to define high-risk SMM.

18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease

Gay F.;Magarotto V.;Palumbo A.;
2016

Abstract

Identification of patient sub-groups with smoldering multiple myeloma (SMM) at high risk of progression to active disease (MM) is an important goal. 18F-FDG PET/CT (positron emission tomography (PET) integrated with computed tomography (PET/CT) using glucose labelled with the positron-emitting radionuclide 18 F) allows for assessing early skeletal involvement. Identification of osteolytic lesions by this technique has recently been incorporated into the updated International Myeloma Working Group criteria for MM diagnosis. However, no data are available regarding the impact of focal lesions (FLs) without underlying osteolysis on time to progression (TTP) to MM. We hence prospectively studied a cohort of 120 SMM patients with PET/CT. PET/CT was positive in 16% of patients (1 FL: 8, 2 FLs: 3, >3 FLs: 6, diffuse bone marrow involvement: 2). With a median follow-up of 2.2 years, 38% of patients progressed to MM, in a median time of 4 years, including 21% with skeletal involvement. The risk of progression of those with positive PET/CT was 3.00 (95% confidence interval 1.58-5.69, P=0.001), with a median TTP of 1.1 versus 4.5 years for PET/CT-negative patients. The probability of progression within 2 years was 58% for positive versus 33% for negative patients. In conclusion, PET/CT positivity significantly increased the risk of progression of SMM to MM. PET/CT could become a new tool to define high-risk SMM.
30
2
417
422
http://www.nature.com/leu/index.html
Aged; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Multiple Myeloma; Osteolysis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Positron-Emission Tomography
Zamagni E.; Nanni C.; Gay F.; Pezzi A.; Patriarca F.; Bello M.; Rambaldi I.; Tacchetti P.; Hillengass J.; Gamberi B.; Pantani L.; Magarotto V.; Versari A.; Offidani M.; Zannetti B.; Carobolante F.; Balma M.; Musto P.; Rensi M.; Mancuso K.; Dimitrakopoulou-Strauss A.; Chauvie S.; Rocchi S.; Fard N.; Marzocchi G.; Storto G.; Ghedini P.; Palumbo A.; Fanti S.; Cavo M.
File in questo prodotto:
File Dimensione Formato  
[Publisher Version] Zamagni et al - 2016 - 18F-FDG PET CT.pdf

Accesso riservato

Descrizione: [Publisher Version] Zamagni et al - 2016 - 18F-FDG PET CT
Tipo di file: PDF EDITORIALE
Dimensione 236.58 kB
Formato Adobe PDF
236.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1732818
Citazioni
  • ???jsp.display-item.citation.pmc??? 37
  • Scopus 93
  • ???jsp.display-item.citation.isi??? 85
social impact